PR Newswire Clinical TrialsOriginal article
Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer's Disease
Data ReadoutpositiveCircPATH™Positive
AI Analysis
Summary
Circular Genomics unveiled its CircPATH™ platform for early Alzheimer's detection based on a Nature Medicine study showing blood-based circular RNA biomarkers outperform gold-standard tests across nearly 2,400 individuals and enable risk stratification years before symptom onset.
Clinical Trial Data
Primary Endpoint
Met
Patients
2,400
Outcome Details
Blood-based circular RNA biomarkers outperformed gold-standard tests and enabled preclinical risk stratification years before symptom onset
Importance:6/10
Sentiment:
0.85
biomarkerAlzheimer's diseaseearly detectioncircular RNAdiagnosticNature Medicine publication
Read the original article
Published by PR Newswire Clinical Trials on July 2, 2026 10:00 AM